Diamyd Medical AB (publ) (DMYD-B.ST)
Stockholm · SEK · Healthcare · Biotechnology
SEK 0.99 (-1.00%) as of
Key statistics
- Market cap
- 153.43M
- EPS (TTM)
- -2.0000
- Dividend yield
- 0.00%
- 52-week range
- 0.8960 – 17.8800
- Beta
- 2.20
- Revenue (TTM)
- 477k
- Profit margin
- 0.00%
- Volume
- 447.19k
About Diamyd Medical AB (publ)
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. It develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. The company was incorporated in 1984 and is headquartered in Stockholm, Sweden.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Stockholm, Sweden
- Employees
- 39
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.